Aptevo Therapeutics Inc. (APVO) Form 8-K — Aug 13, 2026
Aptevo Therapeutics closed approximately $4.5 million in gross financing on August 13, 2026, combining a warrant inducement and a private placement priced at $4.03 per share. Existing warrant holders exercised warrants on 254,922 shares for roughly $1.0 million, and PIPE investors agreed to buy up to 861,708 shares (or pre-funded warrants) in the same price range. As consideration, Aptevo issued new unregistered warrants covering 1,274,610 inducement shares and 4,308,540 common-warrant shares, all struck at $4.03, exercisable only after a required stockholder approval and carrying five-year terms.
Key figures
- Gross Proceeds
- 4500000
- Offering Price
- 4.03
- Shares Offered
- 861708
- Placement agent fee
- 7% of aggregate gross proceeds
- Common warrant shares
- 4308540
- Warrant coverage ratio
- 5:1
- Inducement gross proceeds
- approximately $1.0 million
- Inducement warrant shares
- 1274610
- Inducement exercise shares
- 254922
- Stockholder approval meeting
- reasonable best efforts within 60 days of closing
- Beneficial ownership limitation
- 4.99% or 9.99%
- Pre funded warrant exercise price
- 0.0001
- Expected registration effectiveness
- September 26, 2026 (October 26, 2026 if full SEC review)
- Resale registration filing deadline
- August 22, 2026
- Placement agent legal expense reimbursement cap
- 100000
Price after filing
Close on the filing date to close N calendar days later (from $3.40). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.